Side-by-side · Research reference
LL-37vsPinealon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED15/35 cited
BHuman-MechanisticAUTO-DRAFTED12/36 cited
LL-37
Cathelicidin · Human AMP
Broad-spectrumAntimicrobial activity
Endogenous · Secreted at inflammation sites
Pinealon
Pineal-derived · Neuroprotective
SQ or IM · Daily for 10 days · 1-2×/year
01Mechanism of Action
Parameter
LL-37
Pinealon
Primary target
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
Pathway
hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
Downstream effect
Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026Zhang 2026
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Feedback intact?
—
—
Origin
Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Antibody development
—
—
02Dosage Protocols
Parameter
LL-37
Pinealon
Endogenous expression
Constitutive in neutrophils, epithelial tissues
Upregulated during infection and inflammation.Pinheiro 2026
—
Exogenous (experimental)
Dose varies by study; antimalarial ~10–50 μM in vitro
No FDA-approved exogenous formulation.
—
Plasma levels (malaria)
Elevated in infected patients and miceHe 2026
Exogenous administration reduced parasitemia in murine models.He 2026
—
Evidence basis
In vitro, animal models, human observational
Russian clinical trials + in vitroKhavinson 2014
Frequency
—
Once daily during cycle
Lower / starter dose
—
2.5 mg / day
Duration
—
10-day cycles, 1–2× per year
Reconstitution
—
Bacteriostatic water
Timing
—
No specific time
Half-life
—
Hours
04Side Effects & Safety
Parameter
LL-37
Pinealon
Cytotoxicity (high dose)
Membrane disruption in host cells at supraphysiological concentrations
—
Pro-inflammatory signaling
Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026
—
Theoretical cancer risk
Immunomodulatory roles in tumor microenvironment under investigation
—
Injection site reaction
—
Mild irritation
Long-term safety
—
Limited Western data
Pregnancy / OB
—
Avoid
Absolute Contraindications
LL-37
—Pinealon
- ·Pregnancy / breastfeeding
Relative Contraindications
LL-37
- ·Active autoimmune disease (theoretical immune dysregulation)
Pinealon
- ·Active malignancy (theoretical via gene expression modulation)
05Administration Protocol
Parameter
LL-37
Pinealon
1. Natural secretion
LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.
Add 1–2 mL bacteriostatic water to 10 mg vial.
2. Experimental formulations
Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.
SQ — abdomen preferred.
3. Stability considerations
LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026
Daily during cycle, any time.
4. Storage
—
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
5. Needle
—
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
LL-37
— no documented stacks
Pinealon
+ Epitalon
ModeratePinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.
- Pinealon
- 5–10 mg SQ · daily × 10 days
- Epitalon
- 5–10 mg SQ · daily × 10 days (overlap or alternate)
- Primary benefit
- Neuroprotection + telomere preservation